Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response of SQ tree SLIT-tablet in allergic rhinoconjunctivitis
NCT02481856Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Jun 2015
- Primary completion
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SQ SLIT-tablet in allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by ALK-Abelló. Primary endpoint: Total Rhinoconjunctivitis Symptom Score at 24 weeks. Started Jun 2015; status: completed.
02
Drugs
SQ SLIT-tablet
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02481856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481856.